KIT and chronic myelogenous leukemia, BCR-ABL1 positive: While the multi-kinase, type II inhibitor AP24534 (ponatinib) has been specifically developed to target the gatekeeper mutation in the BCL-ABL fusion protein occurring in response to imatinib treatment of chronic myeloid leukaemia (O'Hare et al., 2009, Choi et al., 2010a), TKI258 (dovitinib) was originally developed as a novel class of RTK inhibitors targeting FLT3, KIT, VGFR and some PDGFR members, in addition to FGFR1-3 (Renhowe et al., 2009).